Cetuximab is a monoclonal antibody with activity against colorectal cancers that overexpress epidermal growth factor receptor. This agent blocks epidermal growth factor receptor signaling and ...

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

Cetuximab therapy was started on the day radiation therapy began with a loading dose of 400 mg/m 2 in the first week, and then 250 mg/m 2 /week for the successive radiation weeks. One cycle of ...